Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEPADIN vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Hypertension,Diabetic nephropathy in patients with type 2 diabetes and hypertension,Heart failure (NYHA class II-IV) as adjunctive therapy,Stroke prevention in hypertensive patients with left ventricular hypertrophy
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.
1.34 mg (one capsule) orally twice daily.
12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes glucuronidation.
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Primarily renal excretion (70-80% unchanged) with minor biliary/fecal elimination (10-15%)
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
95-98% bound primarily to albumin
92% bound to albumin.
0.2-0.4 L/kg indicating moderate tissue distribution
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Oral: 60-75%; complete with IV administration
Oral: 68% ± 12% due to first-pass metabolism.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, reduce dose by 50% or increase dosing interval to every other day.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
Not approved for pediatric use.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Initiate at 2.5 mg once daily; titrate slowly due to increased sensitivity and risk of falls.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
None
None.
Fetal toxicity: Use in pregnancy can cause fetal harm; discontinue as soon as possible when pregnancy is detected,Hypotension in volume-depleted patients,Renal function deterioration in patients with bilateral renal artery stenosis or single kidney,Hyperkalemia, especially in renal impairment or concomitant use of potassium-sparing diuretics,Avoid use with aliskiren in patients with diabetes
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
Pregnancy (second and third trimesters),Hypersensitivity to bepadin or any component,Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min)
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
No significant food interactions reported. Grapefruit juice does not affect bepotastine metabolism. Avoid excessive alcohol intake due to potential for increased sedation.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use with caution; may cause fetal bradycardia and hypotension.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
Not known if excreted in human milk. M/P ratio not established. Caution advised; consider risk-benefit. Monitor infant for excessive sedation and feeding difficulties.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
No standard dose adjustment recommended; however, increased renal clearance and volume of distribution may require dose increase or more frequent administration. Monitor clinical response and adjust based on therapeutic drug monitoring if available.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
BEPADIN (bepotastine besilate), a second-generation antihistamine, is indicated for allergic rhinitis and urticaria. It does not require hepatic metabolism, making it suitable for patients with liver impairment. Onset of action is within 1 hour. Avoid concurrent use with CNS depressants due to additive sedative effects.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Take once daily in the morning or as directed by your physician.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness.,Avoid alcohol consumption as it can intensify drowsiness.,Report any severe allergic reactions, such as difficulty breathing or swelling, to your healthcare provider immediately.,Store at room temperature away from moisture and heat.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEPADIN vs ACTAHIST, answered by our medical review team.
BEPADIN is a Ophthalmic Antihistamine that works by Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEPADIN and ACTAHIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEPADIN is: 5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEPADIN and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEPADIN is classified as Category C. Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.